Royal Bank of Canada Analysts Give Catalent (CTLT) a $44.00 Price Target

Share on StockTwits

Catalent (NYSE:CTLT) received a $44.00 target price from investment analysts at Royal Bank of Canada in a research report issued on Wednesday. The brokerage currently has a “buy” rating on the stock. Royal Bank of Canada’s price objective would suggest a potential upside of 15.73% from the stock’s current price.

A number of other analysts have also recently weighed in on the company. UBS Group started coverage on Catalent in a research report on Tuesday, October 9th. They issued a “neutral” rating and a $48.00 price target for the company. JPMorgan Chase & Co. boosted their price target on Catalent from $50.00 to $55.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 29th. Zacks Investment Research cut Catalent from a “buy” rating to a “hold” rating in a research report on Thursday, July 26th. ValuEngine cut Catalent from a “buy” rating to a “hold” rating in a research report on Tuesday. Finally, First Analysis raised Catalent from a “neutral” rating to an “outperform” rating and cut their price objective for the stock from $47.00 to $43.00 in a research report on Wednesday. Five equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $48.30.

Shares of NYSE:CTLT traded up $1.91 on Wednesday, reaching $38.02. The company had a trading volume of 865,737 shares, compared to its average volume of 636,265. Catalent has a twelve month low of $34.24 and a twelve month high of $47.87. The stock has a market capitalization of $6.11 billion, a P/E ratio of 23.91, a P/E/G ratio of 2.50 and a beta of 1.45. The company has a debt-to-equity ratio of 2.44, a current ratio of 2.15 and a quick ratio of 1.79.

Catalent (NYSE:CTLT) last announced its quarterly earnings results on Tuesday, November 6th. The company reported $0.22 earnings per share for the quarter, missing analysts’ consensus estimates of $0.24 by ($0.02). Catalent had a return on equity of 20.42% and a net margin of 3.39%. The company had revenue of $551.80 million during the quarter, compared to analyst estimates of $582.44 million. During the same period in the prior year, the firm earned $0.21 EPS. Catalent’s quarterly revenue was up 1.5% on a year-over-year basis. As a group, research analysts expect that Catalent will post 1.72 EPS for the current fiscal year.

In other Catalent news, Director Donald E. Morel, Jr. acquired 10,000 shares of the business’s stock in a transaction that occurred on Thursday, September 13th. The stock was acquired at an average price of $43.00 per share, with a total value of $430,000.00. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Lance Miyamoto sold 6,525 shares of the business’s stock in a transaction dated Tuesday, October 16th. The stock was sold at an average price of $42.50, for a total value of $277,312.50. The disclosure for this sale can be found here. Insiders have sold a total of 184,335 shares of company stock valued at $8,161,727 in the last three months. 1.40% of the stock is owned by insiders.

A number of institutional investors and hedge funds have recently modified their holdings of CTLT. Nelson Van Denburg & Campbell Wealth Management Group LLC bought a new position in Catalent during the second quarter valued at about $145,000. Moneta Group Investment Advisors LLC increased its stake in Catalent by 105.0% during the second quarter. Moneta Group Investment Advisors LLC now owns 3,515 shares of the company’s stock valued at $147,000 after acquiring an additional 1,800 shares during the period. CIBC Asset Management Inc bought a new position in Catalent during the third quarter valued at about $217,000. Hartford Investment Management Co. bought a new position in Catalent during the second quarter valued at about $220,000. Finally, Rehmann Capital Advisory Group increased its stake in Catalent by 1,895.9% during the second quarter. Rehmann Capital Advisory Group now owns 5,309 shares of the company’s stock valued at $222,000 after acquiring an additional 5,043 shares during the period. Hedge funds and other institutional investors own 92.08% of the company’s stock.

About Catalent

Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.

Read More: What are the benefits of a balanced fund?

Analyst Recommendations for Catalent (NYSE:CTLT)

Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply